文献速递炎症性肠病

验证药物耐受性抗英夫利西单抗和抗阿达木单抗抗体检测试剂盒的阳性阈值

Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
PubMed 文献 · Aliment Pharmacol Ther · 2020-11-23

研究基于498名未使用过抗TNF药物的健康成人血清确定IDKmonitor药物耐受性抗英夫利西单抗和抗阿达木单抗抗体检测的阳性阈值,并在治疗药物监测队列和PANTS队列中验证。新阈值低于厂家推荐的10 AU/mL,分别为9和6 AU/mL。在治疗药物监测队列中,更多阿达木单抗治疗患者被重新分类为抗体阳性,且低浓度抗阿达木单抗抗体与较低药物水平和治疗失败相关。

要点

  • 新阳性阈值(抗英夫利西单抗9 AU/mL、抗阿达木单抗6 AU/mL)低于厂家阈值10 AU/mL。
  • 阿达木单抗治疗患者中11.2%被重新分类为抗体阳性,英夫利西单抗为3.1%。
  • 抗阿达木单抗抗体≥新阈值与原发性无应答和54周未缓解相关。

核心结论

  • 实验室应针对所用检测方法自行确定抗体阳性阈值。
  • 对于阿达木单抗,低浓度抗药物抗体与较低药物水平和治疗失败相关。

研究设计与样本

  • 使用498名未使用过抗TNF药物的健康成人血清(来自Exeter Ten Thousand研究)确定阳性阈值,并在治疗药物监测服务和PANTS队列中验证。

主要发现

  • 抗英夫利西单抗和抗阿达木单抗抗体的99百分位浓度80%单侧置信区间下限分别为9和6 AU/mL,低于厂家阈值10 AU/mL。
  • 在治疗药物监测队列中,阿达木单抗治疗患者被重新分类为抗体阳性的比例高于英夫利西单抗治疗患者(11.2% [814/7272] vs 3.1% [390/12 683],P < 0.0001)。
  • 重新分类组阿达木单抗药物浓度(中位数8.1,IQR 5.5-11.0 mg/L)低于新阈值以下组(<5 AU/mL)(中位数9.9,IQR 7.1-13.0 mg/L;P < 0.0001),但高于厂家阈值组(10-29 AU/mL)(中位数5.9 mg/L,IQR 3.5-8.7;P < 0.0001)。
  • 使用新阈值或厂家阈值时,英夫利西单抗药物浓度无差异(P = 0.11)。
  • 在PANTS队列中,抗阿达木单抗抗体浓度≥新阈值患者比低于新阈值(0-5 AU/mL)患者更可能原发性无应答(25/68 [37%] vs 64/332 [19%],P = 0.0035)和54周未缓解(51/62 [82%] vs 168/279 [60%],P = 0.0011);抗英夫利西单抗抗体未见此现象。

关键数值与推荐

  • 抗英夫利西单抗抗体阳性阈值9 AU/mL,抗阿达木单抗抗体阳性阈值6 AU/mL。

临床怎么用

  • 实验室应针对所用检测方法自行确定抗体阳性阈值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: When used proactively, drug-tolerant anti-tumour necrosis factor (TNF) antibody assays provide early opportunity to suppress immunogenicity. AIM: To validate positivity thresholds of IDKmonitor drug-tolerant anti-infliximab and -adalimumab antibody assays. METHODS: We applied positivity thresholds, defined by testing sera from 498 anti-TNF naive healthy adults, from the Exeter Ten Thousand study to data from our therapeutic drug monitoring (TDM) service and Personalised Anti-TNF Therapy in Crohn's disease (PANTS) cohort to explore associations with drug level and treatment outcomes. RESULTS: The 80% one-sided lower confidence interval of the 99th centile concentration for anti-infliximab and -adalimumab antibodies were lower than the manufacturers threshold of 10 arbitrary units (AU)/mL; 9 and 6 AU/mL, respectively. Using these new thresholds in the TDM cohort, more adalimumab- than infliximab- (11.2% [814/7272] vs 3.1% [390/12 683] P < 0.0001) treated patients were reclassified as antibody-positive. Adalimumab drug concentrations in this reclassified group (median 8.1, interquartile range [IQR] 5.5-11.0 mg/L) were lower than those below the new threshold (<5AU/mL) (median 9.9, IQR 7.1-13.0 mg/L; P < 0.0001), but higher than at the manufacturer's threshold (10-29 AU/mL) (median 5.9 mg/L, IQR 3.5-8.7; P < 0.0001). No difference in infliximab drug concentration was observed using the new or manufacturer's positivity threshold (P = 0.11). In the PANTS cohort, patients with anti-adalimumab antibody concentrations at or above the new threshold were more likely to be in primary non-response (25/68 [37%] vs. 64/332 [19%], P = 0.0035), and non-remission at week 54 (51/62 [82%] vs. 168/279 [60%], P = 0.0011), than patients with anti-drug antibody concentrations in the group below the new threshold (0-5 AU/mL); this was not seen for anti-infliximab antibodies. CONCLUSION: Laboratories should derive antibody positivity thresholds for assays they use. For adalimumab, low-concentration anti-drug antibodies were associated with lower drug levels and treatment failure.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nice R, Chanchlani N, Green H, et al. Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. Aliment Pharmacol Ther. 2020. PMID: 33226651. doi:10.1111/apt.16135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。